Physician profile
Eli Roza
NPI 1184611444
$78,843.23
in general payments reported to CMS, 2019-2025
38 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,838 · 2020: $2,568 · 2021: $12K · 2022: $13K · 2023: $19K · 2024: $21K · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $5,654 · Travel and Lodging: $2,755 · Education: $95.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,340.00 |
| Food and Beverage | $5,654.04 |
| Travel and Lodging | $2,755.13 |
| Education | $95.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $40,672.64 | 2019-2025 | Farxiga |
| Vifor Pharma, INC. | $11,597.42 | 2019-2024 | Korsuva, Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,800.41 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $9,090.09 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Ani Pharmaceuticals, INC. | $629.68 | 2022-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $601.37 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $597.97 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $562.08 | 2019-2025 | Rayaldee |
| Novo Nordisk INC | $483.95 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Mallinckrodt Hospital Products INC. | $426.28 | 2020-2024 | Acthar |
| Akebia Therapeutics INC | $367.19 | 2019-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $330.20 | 2022-2025 | Tarpeyo |
| Amgen INC. | $291.34 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Travere Therapeutics, INC. | $291.33 | 2019-2025 | Filspari |
| Fresenius USA Marketing, INC. | $274.53 | 2019-2025 | Velphoro, Velphoro |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Roza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.